Boehringer Ingelheim, Gubra to validate new Peptides for obesity
Boehringer Ingelheim has entered into a new research and licensing agreement with biotech company Gubra to identify and validate innovative peptides to treat obesity. The new partnership builds
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.